Aaron Lisberg, MD

Dr. Aaron Lisberg specializes in medical oncology with an emphasis on clinical and translational research in thoracic oncology. Throughout his medical training, he coauthored a number of high-impact peer-reviewed publications in areas such as stem cell therapy, skin cancer and lung cancer. During his first year on the faculty at UCLA he was the first author of three high profile lung cancer publications. Currently, he is leading a number of research projects aimed at further characterizing the application of immunotherapy in thoracic malignancies and is building a clinical trial portfolio to compliment his translational research interests, with an emphasis on novel immunotherapeutic approaches. As a result of his efforts, he has presented his research at numerous scientific meetings both domestically and abroad.

Lisberg A, Tucker DA, Goldman JW, Wolf B, Carroll J, Hardy A, Morris K, Linares P, Adame C, Spiegel ML, Wells C, McKenzie J, Ledezma B, Mendenhall M, Abarca P, Bornazyan K, Hunt J, Moghadam N, Chong N, Nameth D, Marx C, Madrigal J, Vangala S, Shaverdian N, Elashoff D, Garon EB. Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. Cancer Immunol Res. 2018 Jan 30. doi: 10.1158/2326-6066.CIR-17-0063. [Epub ahead of print]

Ellis-Caleo T, Lisberg A, Tucker DA, Garon EB. High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studies. J Thorac Dis. 2018 Feb;10(Suppl 3):S397-S403. doi: 10.21037/jtd.2018.01.110.

Lisberg A, Cummings A, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledezma B, Mendenhall M, Hunt J, Wolf B, Jones B, Madrigal J, Horton J, Spiegel M, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Lim C, Ma L, Adame C, Garon EB. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC. J Thorac Oncol. 2018 Aug;13(8):1138-1145. doi: 10.1016/j.jtho.2018.03.035. Epub 2018 Jun 1.

Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017 Jul;18(7):895-903. doi: 10.1016/S1470-2045(17)30380-7. Epub 2017 May 24. Erratum in: Lancet Oncol. 2017 Jul;18(7):e371.

Spiegel ML, Goldman JW, Wolf BR, Nameth DJ, Grogan TR, Lisberg AE, Wong DJL, Ledezma BA, Mendenhall MA, Genshaft SJ, Gutierrez AJ, Abtin F, Wallace WD, Adame CR, McKenzie JR, Abarca PA, Li AJ, Strunck JL, Famenini S, Carroll JM, Tucker DA, Sauer LM, Moghadam NM, Elashoff DA, Abaya CD, Brennan MB, Garon EB. Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. Cancer. 2017 Dec 15;123(24):4800-4807. doi: 10.1002/cncr.31056. Epub 2017 Nov 10. Review.